Suppr超能文献

在原发性可手术乳腺癌的淋巴结阳性患者中检测淋巴管浸润是否有用?

Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer?

机构信息

Department of Pathology, Bergonié Institute, Regional Cancer Center, Bordeaux Cedex, France.

出版信息

Cancer. 2010 Jul 1;116(13):3093-101. doi: 10.1002/cncr.25137.

Abstract

BACKGROUND

Lymphovascular invasion (LVI) is a widely recognized prognostic factor in lymph node-negative breast cancers. However, there are only limited and controversial data about its prognostic significance in lymph node-positive patients.

METHODS

Among 931 patients operated on and monitored at the authors' institution for an invasive breast carcinoma between 1989 and 1992, all 374 lymph node-positive breast cancers entered the study (median follow-up, 126 months).

RESULTS

LVI was present in 46% of tumors and was associated with age < or = 40 years (P = .02), high histological grade (P = .01), and negative estrogen receptor status (P = .032), but not with tumor size, number of involved lymph nodes, or HER-2/neu status. LVI was an independent prognostic factor for distant metastases (P = .002). Furthermore, in HER-2/neu-negative/hormone receptor-positive (n = 287) tumors, the number of independent prognostic factors (LVI, age, histological grade, number of involved lymph nodes, and tumor size) was associated with a 5-years metastasis-free survival ranging from 100% if no factors (n = 25) to 89% +/- 2% if 1 or 2 factors (n = 186) and 67% +/- 6 if 3, 4, or 5 factors (n = 76) were present (P < .001).

CONCLUSIONS

LVI is an independent prognostic factor in lymph node-positive breast cancer and merits further prospective investigations as a decision tool in the adjuvant chemotherapy setting.

摘要

背景

淋巴管浸润(LVI)是淋巴结阴性乳腺癌的一个广泛认可的预后因素。然而,关于其在淋巴结阳性患者中的预后意义,仅有有限且有争议的数据。

方法

在作者机构于 1989 年至 1992 年间对浸润性乳腺癌进行手术和监测的 931 例患者中,所有 374 例淋巴结阳性乳腺癌均进入研究(中位随访时间 126 个月)。

结果

LVI 存在于 46%的肿瘤中,与年龄≤40 岁(P=0.02)、高组织学分级(P=0.01)和阴性雌激素受体状态(P=0.032)相关,但与肿瘤大小、受累淋巴结数量或 HER-2/neu 状态无关。LVI 是远处转移的独立预后因素(P=0.002)。此外,在 HER-2/neu 阴性/激素受体阳性(n=287)肿瘤中,独立预后因素(LVI、年龄、组织学分级、受累淋巴结数量和肿瘤大小)的数量与 5 年无转移生存率相关,如果没有因素(n=25)则为 100%,如果有 1 或 2 个因素(n=186)则为 89%±2%,如果有 3、4 或 5 个因素(n=76)则为 67%±6%(P<0.001)。

结论

LVI 是淋巴结阳性乳腺癌的独立预后因素,值得进一步前瞻性研究,作为辅助化疗中决策工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验